The Antiplatelet activity of ketamine is mediated through suppression of phosphoinositide breakdown and an increase in cyclic GMP.

許準榕Chang; Y.; Chen; T.L.; Hsiao; G.; Shen; M.Y.; Lin; K.H.; Chou; D.S.; Lin; C.H.; Sheu; J.R.2026-05-222026-05-222004https://203.71.86.71/handle/123456789/34147en-US醫學科學研究所期刊論文The Antiplatelet activity of ketamine is mediated through suppression of phosphoinositide breakdown and an increase in cyclic GMP.article